Abstracts Archive - Page 52 of 2607 - ACR Meeting Abstracts

Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 0020 • ACR Convergence 2025
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Anne Carlton, Lam Tsoi, Joseph Kirma, Jennifer Fox, Paul Harms and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Vasculitis encompasses multiple conditions united by end-organ damage due to an immune-mediated reaction against the vasculature. Leukocytoclastic vasculitis (LCV) is a subtype of cutaneous…
Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Virginia Carrizo Abarza¹, Pankti Mehta², Fadi Kharouf³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…
Abstract Number: 0115 • ACR Convergence 2025
Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
Ajay Tambralli¹, Emily Becker², Kaitlyn Sabb³, NaveenKumar Somanathapura¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan - Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) contribute to antiphospholipid syndrome (APS) pathogenesis. We recently discovered that APS patient neutrophils have more…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0040 • ACR Convergence 2025
Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
Andrew Gibson¹, Jianming Wu², Chaoling Dong¹, R. Curtis Hendrickson¹, Travis Ptacek¹, Jeffrey Edberg¹ and Robert Kimberly¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Minnesota, Saint Paul, MN
Background/Purpose: The Tyrosine Activation Motif (ITAM)-containing FcRg chain, encoded by FCER1G, non-covalently couples with the immunoglobulin binding receptors, -- FcγRI (CD64), FcγRIIIa (CD16), and FcaRI…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Daniel Campos-Martin¹, Nerea Alcorta-Lorenzo², César Antonio Egües Dubuc², Luis Maria Lopez-Dominguez³, Lucia Otero⁴, Fernando Sánchez-Alonso⁵ and Joaquin Maria Belzunegui-Otano⁶, ¹Rheumatology Department, Donostia University Hospital, San Sebastian-Donostia, Pais Vasco, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian-Donostia, Spain
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…
Abstract Number: 0086 • ACR Convergence 2025
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Kiana Chen¹, Chia-Lung Wu², Gulzada Kulzhanova² and Homaira Rahimi³, ¹University of Rochester School of Medicine and Dentistry, Bronx, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].